E-therapeutics Plc
ETXPF · OTC
1/31/2025 | 1/31/2024 | 1/31/2023 | 1/31/2022 | |
|---|---|---|---|---|
| Revenue | $0 | $318 | $475 | $641 |
| % Growth | -100% | -33.1% | -25.9% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $164 |
| Gross Profit | $0 | $318 | $475 | $477 |
| % Margin | – | 100% | 100% | 74.4% |
| R&D Expenses | $14,433 | $10,247 | $8,900 | $8,215 |
| G&A Expenses | $4,208 | $3,859 | $3,484 | $3,935 |
| SG&A Expenses | $4,213 | $3,865 | $3,490 | $4,998 |
| Sales & Mktg Exp. | $5 | $6 | $6 | $1,063 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $18,646 | $14,112 | $10,714 | $13,213 |
| Operating Income | -$18,646 | -$13,794 | -$10,239 | -$12,831 |
| % Margin | – | -4,337.7% | -2,155.6% | -2,000.4% |
| Other Income/Exp. Net | $1,037 | $713 | $119 | $51 |
| Pre-Tax Income | -$17,609 | -$13,081 | -$10,120 | -$12,796 |
| Tax Expense | $2,740 | -$1,915 | -$1,846 | -$1,948 |
| Net Income | -$14,869 | -$11,166 | -$8,274 | -$10,848 |
| % Margin | – | -3,511.3% | -1,741.9% | -1,691.2% |
| EPS | -0.02 | -0.019 | -0.015 | -0.022 |
| % Growth | -5.2% | -24% | 30.6% | – |
| EPS Diluted | -0.02 | -0.019 | -0.015 | -0.022 |
| Weighted Avg Shares Out | 740,636 | 584,363 | 537,377 | 488,342 |
| Weighted Avg Shares Out Dil | 740,619 | 584,335 | 537,346 | 488,342 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $713 | $242 | $61 |
| Interest Expense | $0 | $0 | $23 | $10 |
| Depreciation & Amortization | $172 | $71 | $468 | $260 |
| EBITDA | -$18,474 | -$13,723 | -$9,281 | -$9,522 |
| % Margin | – | -4,315.4% | -1,953.9% | -1,484.5% |